2023 Guidance and Q3 Earnings
Vaccines: +34% with strong Arexvy launch contributing £709m
AREXVÝ*
(RESPIRATORY SYNCYTIAL VIRUS
VACCINE, ADJUVANTED)
83m adults age 60+ in US; 400m globally
Launches underway in US, Europe and Canada;
approval in Japan
>60% US retail market share
~50% of doses co-administered with flu vaccines
Available in all major US retail pharmacies
94.6% efficacy in comorbid population resonating
well with 66% of HCPs², recalling Arexvy by name³
~1.4 million US adults vaccinated during Q3
TRX (m)
1.4
Arexvy US TRX since launch
1.2
1
0.8
0.6
0.4
0.2
0
31
32
33
34
35
36
37
38
39
Week number
Arexvy
Competitor
GSK
Absolute values at AER; changes at CER, unless stated otherwise 1. Excluding COVID-19 solutions 2. Healthcare Professionals
3. US HCP RSV ATU: Jun 22 (n=260), Jun 23 (n=147), Jul 23 (n=145), Aug 23 (n=149)
15View entire presentation